Journal article · 2023 · Open access

5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice

MT Gómez Lluch, P García Lloret, M González Boronat, CV Almeida González

European Journal of Hospital Pharmacy, A137.2–A137 · Published 1 March 2023 · DOI 10.1136/ejhpharm-2023-eahp.286

Open PDFView at the publisherCite this paper

In brief

“5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice” is a 2023 journal article by MT Gómez Lluch and 3 co-authors, published in European Journal of Hospital Pharmacy. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at European Journal of Hospital Pharmacy.

Citations
0
Authors
4

Abstract

Background and Importance Tofacitinib, baricitinib, upadacitinib and filgotinib are Janus kinase inhibitors (IJAKs) indicated in rheumatoid arthritis (RA). The EMA notified that in patients with RA who were ≥50 years with at least one cardiovascular risk factor had an increased risk of major adverse cardiovascular events (MACE), and malignancies with use of tofacitinib relative to TNF-alpha inhibitor: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-xeljanz-tofacitinib-increased-risk-major-adverse_en.pdf Although it is being evaluated, it is still unknown if this risk is shared by other IJAKs. Aim and Objectives To describe and compare the safety of tofacitinib, baricitinib, upadacitinib and filgotinib in patients with RA in a real-world-setting. Secondary objective to analyse if there is a relationship between MACE and malignancies with a patient profile with a higher risk of developing them as established in the alert. Material and Methods Retrospective/prospective observational study of RA patients under treatment with tofacitinib, baricitinib, upadacitinib and filgotinib until September 2022. Safety was determined based on the adverse events (AEs) reported. Variables sex, age at start,time-of-treatment, reason for discontinuation, risk factor´s MACE, risk factors for malignancies, and AEs. Statistical analysis a description of characteristics and events that occurred in the cohort was carried out. Associations were later explored. Results 124 patients (80.6% women) were enrolled. Mean age: 55.8 (SD11.8) years. Treatments received tofacitinib (n=60), upadacitinib (n=49), baricitinib (n=21) and filgotinib (n=14), because 19 patients (15.3%) were treated with more than one IJAKsequentially. Median of treatment; tofacitinib: 399 (171-884) days, baricitinib: 308 (210-632), upadacitinib: 287 (130-477) and 93 (60-171) for filgotinib. We identified 110 patient treatments with an increased risk of MACE or malignances. AEs were reported in 39 (31,5%) treatments (21, 9, 7, and 2 cases with tofacitinib, upadacitinib, baricitinib and filgotinib) being the most common herpes zoster. Only 2 patients suffered a MACE in the total cohort (both with tofacitinib). There were 79 end-of-treatment because of inefficacy (n=46), AE (n=22), both (n=7) or for being considered a risk patient (n=4). No association could be established between risk patient and the development of adverse events, neither minor or major. Conclusion and Relevance Therefore, it is still unknown if the exchange strategy between them is adequate to reduce the risk. Limitation: a larger sample size and longer follow-up time are required to detect major AEs and their association with patients at risk. References and/or Acknowledgements Conflict of Interest No conflict of interest

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Lluch, M. G., Lloret, P. G., Boronat, M. G., & González, C. A. (2023). 5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice. European Journal of Hospital Pharmacy, A137.2–A137. https://doi.org/10.1136/ejhpharm-2023-eahp.286

MLA 9

Lluch, MT Gómez, et al. “5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice.” European Journal of Hospital Pharmacy, 2023, pp. A137.2–A137. https://doi.org/10.1136/ejhpharm-2023-eahp.286.

Chicago

Lluch, MT Gómez, P García Lloret, M González Boronat, and CV Almeida González. 2023. “5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice.” European Journal of Hospital Pharmacy: A137.2–A137. https://doi.org/10.1136/ejhpharm-2023-eahp.286.

Harvard

Lluch, M. G. et al. (2023) ‘5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice’, European Journal of Hospital Pharmacy, pp. A137.2–A137. doi:10.1136/ejhpharm-2023-eahp.286.

IEEE

M. G. Lluch, P. G. Lloret, M. G. Boronat, and C. A. González, “5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice,” European Journal of Hospital Pharmacy, pp. A137.2–A137, 2023, doi: 10.1136/ejhpharm-2023-eahp.286.

BibTeX

@article{lluch2023there,
  title     = {{5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice}},
  author    = {Lluch, MT Gómez and Lloret, P García and Boronat, M González and González, CV Almeida},
  journal   = {European Journal of Hospital Pharmacy},
  year      = {2023},
  pages     = {A137.2--A137},
  doi       = {10.1136/ejhpharm-2023-eahp.286},
  url       = {https://doi.org/10.1136/ejhpharm-2023-eahp.286}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • JAK inhibitors
  • rheumatoid arthritis
  • tofacitinib
  • baricitinib
  • upadacitinib
  • filgotinib
  • major adverse cardiovascular events
  • cancer risk

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Lluch, M. G., Lloret, P. G., Boronat, M. G., & González, C. A. (2023). 5PSQ-073 Is there a safety difference? janus kinase inhibitors in real clinical practice. European Journal of Hospital Pharmacy, A137.2–A137. https://doi.org/10.1136/ejhpharm-2023-eahp.286

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Journal of Hospital Pharmacy: sign in and open the PDF from this page.

Who wrote this paper?

MT Gómez Lluch, P García Lloret, M González Boronat, CV Almeida González.

What is the DOI of this paper?

10.1136/ejhpharm-2023-eahp.286, permanently at https://doi.org/10.1136/ejhpharm-2023-eahp.286. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.